Document Classification

Section Type: RESULTS

Text: At weeks 12 and 24, combined therapy with golimumab plus MTX versus placebo plus MTX significantly improved RAMRIS scores for synovitis (mean -1. 92 versus 0. 14 [P < 0. 001] at week 12 ; -2. 45 versus -1. 04 [P < 0. 001] at week 24), osteitis (mean -1. 82 versus 0. 56 [P < 0. 001] at week 12 ; -2. 27 versus -0. 32 [P < 0. 001] at week 24), and bone erosion (mean -0. 40 versus 0. 24 [P = 0. 016] at week 12 ; -0. 40 versus -0. 24 [P = 0. 010] at week 24).